For the management of Bone and Joint Infections in adults.
Bone infections clinic to provide first four weeks of treatment course. Course to be continued by GP for up to 6 months (individual treatment plans will be provided for each patient), in line with Shared Care Protocol.
APCO September 2018.
For all other indications.
APCO May 2012.
Rifampicin (Rifadin® ) (Solution for infusion)
Formulary
Secondary care use only.
APCO July 2010.
Rifampicin and Isoniazid (Rifinah® 150mg/100mg)
Formulary
Secondary care use only.
APCO July 2010.
Rifampicin and Isoniazid (Rifinah® 300mg/150mg)
Formulary
Secondary care use only.
APCO July 2010.
Rifampicin and Isoniazid and Pyrazinamide (Rifater®)
Rifampicin, isoniazid, pyrazinamide and ethambutol (Voractiv®)
Non Formulary
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Red: Medicines which should only be prescribed in secondary care by a specialist.
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.
Brown: Medicines which should only be prescribed in restricted circumstances.
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.
For meningococcal meningitis prophylaxis in line with 
For the management of Bone and Joint Infections in adults. 
For all other indications.
Unlicensed
